AstraZeneca rejigs commercial ranks around cancer, biopharma in wake of Mallon's departure

With key commercial cog Mark Mallon bound for Ironwood Pharmaceuticals' CEO spot, AstraZeneca is shaking up its corporate structure and revamping top management.

On Monday, the company unveiled plans to create two separate divisions, BioPharmaceuticals and Oncology, each comprising its own R&D and marketing units.